Company profile
GlioCART company profile
GlioCART is a University of Basel spin-out developing the first CAR-T cell therapy for glioblastoma (GBM), an aggressive brain cancer with median survival of 12-18 months. Its dual-action approach targets tumors directly while secreting a CD47-blocker to reprogram immunosuppressive macrophages in the tumor microenvironment, aiming for better efficacy and reduced side effects than standard care.
Business identity
- Operating status
- Active
- Founded
- 2025-11-01, Month
Headquarters
- Headquarters
- Allschwil, Basel-Landschaft, Switzerland
- Country code
- CH
- Continent
- Europe